Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study

Müller, F.; Cugy, E.; Ducerf, Camille; Delleci, C.; Guehl, Dominique; Joseph, Pierre-Alain; Burbaud, Pierre; Dehail, Patrick

doi:10.1177/0269215511412799

Cited by 14 publications

(19 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Management of spasticity in HSP using botulinum toxin injections type A (Btx-A) has been described in some studies 4,5,6,7,8 . An injection of Btx-A is considered effective and safe for the treatment of lower limb spasticity in adults 4,6,8,9,10 and children 5 . Some studies have found that, in general, Btx-A combined with physiotherapy improves comfortable gait velocity 4,6,8 in HSP patients, but it is not yet known whether Btx-A improves non-motor manifestations in these patients.…”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

Servelhere

Faber

Martinez

et al. 2018

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Motor and non-motor manifestations are common and disabling features of hereditary spastic paraplegia (HSP). Botulinum toxin type A (Btx-A) is considered effective for spasticity and may improve gait in these patients. Little is known about the effects of Btx-A on non-motor symptoms in HSP patients. Objective To assess the efficacy of Btx-A on motor and non-motor manifestations in HSP patients. Methods Thirty-three adult patients with a clinical and molecular diagnosis of HSP were evaluated before and after Btx-A injections. Results Mean age was 41.7 ± 13.6 years and there were 18 women. Most patients had a pure phenotype and SPG4 was the most frequent genotype. The Btx-A injections resulted in a decrease in spasticity at the adductor muscles, and no other motor measure was significantly modified. In contrast, fatigue scores were significantly reduced after Btx-A injections. Conclusion Btx-A injections resulted in no significant functional motor improvement for HSP, but fatigue improved after treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

Servelhere

Faber

Martinez

et al. 2018

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Recent evidence-based reviews by the American Academy of Neurology and two international consensus committees came to the conclusion that BoNT is a safe and efficacious treatment for adult spasticity [9][10][11]. Treatmentassociated adverse effects include injection site reactions and muscle weakness, and are usually mild and self-limited if appropriate doses of BoNT are used to treat limb spasticity [12,13].…”

Section: Review Brown Schütz and Simpsonmentioning

confidence: 99%

Botulinum Toxin for Neuropathic Pain and Spasticity: An Overview

2014

View full text Add to dashboard Cite

In recent years, a large body of data has surfaced reporting the therapeutic benefit of botulinum toxin injection in multiple conditions. The aim of this review is: to summarize the highest quality literature pertaining to clinical application of botulinum toxin in neuropathic pain conditions including postherpetic neuralgia, trigeminal neuralgia, diabetic polyneuropathy, post-traumatic neuralgia, carpal tunnel syndrome, complex regional pain syndrome, phantom limb and stump pain, and occipital neuralgia; to provide an overview of the clinical trials using botulinum toxin in adult spasticity; and to assign levels of evidence according to the American Academy of Neurology guidelines. In summary, there is level A evidence for established efficacy in postherpetic neuralgia and adult spasticity; level B evidence for probable efficacy in trigeminal neuralgia and post-traumatic neuralgia; level B evidence for probable lack of efficacy in carpal tunnel syndrome; level C evidence for possible efficacy in diabetic polyneuropathy; and level U (insufficient) evidence in complex regional pain syndrome, phantom limb and stump pain, and occipital neuralgia.

show abstract

“…The benefit from BoNT-A is maintained after repeated treatment cycles(66-67) and thus, BoNT-A has been thought to be a first line treatment in focal/multifocal spasticity (68). In addition, BoNT treatment has been shown to improve associated reactions in ULS(69) reduce predetermined disability parameters (including pain) (70)(71)(72)(73), reduce carer burden (70,(73)(74), improve person-centered goals(75) and self-reported efficacy with safety (76). However, efficacy of BoNT-A for improvement of motor control and active functions have not been attained (77).…”

Section: Evidence-based Medicinementioning

confidence: 99%

Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, Evidences and Clinical Context

Rosales¹

2012

Dystonia - The Many Facets

View full text Add to dashboard Cite

Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study

Abstract: Self-reported adverse events following botulinum toxin injections in spasticity are rare, often benign and of short duration in current clinical practice. Botulinum toxin is considered effective by patients in treating spasticity of the upper and lower limbs.

Cited by 14 publications

References 9 publications

Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

Botulinum Toxin for Neuropathic Pain and Spasticity: An Overview

Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, Evidences and Clinical Context

Contact Info

Product

Resources

About